EU5 Embolization Particle Procedures Count by Segments and Forecast to 2030

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3995
Buy Report View Sample

Published: April 28, 2023 Report Code: GDMEPD0818R27-ST

Select Item

EU5 Embolization Particle Procedures Market Report Overview

The total number of Embolization Particle Procedures performed in EU5 was 16,692 in 2022. In procedures using embolization particles, a small catheter is placed inside a blood vessel to reach the area that is bleeding, and the catheter is navigated under image guidance to the farthest point with other different embolic materials that help block the bleeding vessels.

EU5 Embolization Particle Procedures market research report is a comprehensive databook, covering key procedures data on the EU5 Embolization Particle Procedures.

EU5 Embolization Particle Procedures Market Segmentation

The key segments in the EU5 Embolization Particle Procedures market are Embolization Particle Procedures to treat Benign prostatic hyperplasia, Embolization Particle Procedures to treat Uterine Fibroids, Embolization Particle Procedures to treat Hepatocellular Carcinoma, Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Embolization Particle Procedures to treat Renal Cell Carcinoma, Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, and Embolization Particle Procedures to treat Arteriovenous Malformations. Embolization Particle Procedures to treat Benign Prostatic hyperplasia dominated the EU5 Embolization Particle Procedures market in terms of volume.

Embolization Particle Procedures to treat Benign prostatic hyperplasia:

Embolization Particle Procedures to treat benign prostatic hyperplasia (BPH) includes sub-segments such as procedures using microspheres and procedures using polyvinyl alcohol (PVA) particles. Lower urinary tract infections caused by BPH is treated by Prostatic artery embolization (PAE), an embolization procedure. A tiny hole is made in the groin to execute Prostatic artery embolization. Through the artery, a catheter is inserted and pointed at the prostate. Once the catheter is in the prostate’s blood vessel, a little amount of material is injected to limit blood flow by plugging the artery.

Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease:

Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease includes sub-segments such as Procedures using Drug-Eluting Beads, Procedures using Microspheres, Procedures using Polyvinyl Alcohol (PVA) Particles and Procedures using Radioembolization Particles. One of the main causes of death from colorectal cancer is liver metastases. By Embolization procedure, embolization substances are directly injected through a catheter into the colon to block or reduce the blood flow to the tumor.

EU5 Embolization Particle Procedures Market by Segments, 2022(%)

EU5 Embolization Particle Procedures Market by Segments, 2022(%)

For more insights on the segments of EU5 Embolization Particle Procedures market, download a free report sample

EU5 Embolization Particle Procedures Market by Country

The key countries in the EU5 Embolization Particle Procedures market are France, Germany, Italy, Spain, and the UK. In the year 2022, Germany dominated the EU5 Embolization Particle Procedures market, followed by the UK and France respectively.

EU5 Embolization Particle Procedures Market by Country, 2022(%)

EU5 Embolization Particle Procedures Market by Country, 2022(%)

For more country insights on EU5 Embolization Particle Procedures market, download a free report sample

EU5 Embolization Particle Procedures Market Outlook

Market Size (2022) 16,692
Historical period 2015-2022
Forecast period 2023-2030
Key Segments Embolization Particle Procedures to treat Benign prostatic hyperplasia, Embolization Particle Procedures to treat Uterine Fibroids, Embolization Particle Procedures to treat Hepatocellular Carcinoma, Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Embolization Particle Procedures to treat Renal Cell Carcinoma, Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, and Embolization Particle Procedures to treat Arteriovenous Malformations
Key Countries France, Germany, Italy, Spain, and the UK

Segments Covered in the Report

EU5 Embolization Particle Procedures Market Segments Outlook (Number of Procedures, 2022)

  • Embolization Particle Procedures to treat Arteriovenous Malformation
  • Procedures using Microspheres
  • Procedures using PolyVinyl Alcohol (PVA) Particles
  • Embolization Particle Procedures to treat Benign Prostatic hyperplasia
  • Procedures using Microspheres
  • Procedures using PolyVinyl Alcohol (PVA) Particles
  • Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease
  • Procedures using Drug-Eluting Beads
  • Procedures using Microspheres
  • Procedures using PolyVinyl Alcohol (PVA) Particles
  • Procedures using Radioembolization
  • Embolization Particle Procedures to treat Hepatocellular Carcinoma
  • Procedures using Drug-Eluting Beads
  • Procedures using Microspheres
  • Procedures using PolyVinyl Alcohol (PVA) Particles
  • Procedures using Radioembolization Particles
  • Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma
  • Procedures using Drug-Eluting Beads
  • Procedures using Microspheres
  • Procedures using PolyVinyl Alcohol (PVA) Particles
  • Procedures using Radioembolization Particles
  • Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease
  • Procedures using Drug-Eluting Beads
  • Procedures using Microspheres
  • Procedures using PolyVinyl Alcohol (PVA) Particles
  • Procedures using Radioembolization Particles
  • Embolization Particle Procedures to treat other tumors with Metastatic Liver Disease
  • Procedures using Drug-Eluting Beads
  • Procedures using Microspheres
  • Procedures using PolyVinyl Alcohol (PVA) Particles
  • Procedures using Radioembolization Particles
  • Embolization Particle Procedures to treat Renal Cell Carcinoma
  • Procedures using Drug-Eluting Beads
  • Procedures using Microspheres
  • Procedures using PolyVinyl Alcohol (PVA) Particles
  • Procedures using Radioembolization Particles
  • Embolization Particle Procedures to treat Uterine Fibroids
  • Procedures using Microspheres
  • Procedures using PolyVinyl Alcohol (PVA) Particles.

EU5 Embolization Particle Procedures Market Country Outlook (Number of Procedures, 2022)

  • France
  • Germany
  • Italy
  • Spain
  • UK

Reasons to Buy

The EU5 Embolization Particle Procedures report helps you to develop –

  • Business strategies by identifying the key segments poised for strong growth in the future.

  • Market-entry and market expansion strategies.

  • Develop investment strategies by identifying the key segments expected to register strong growth in the near future.

Table of Contents

  • 1 Table of Contents

    • 1.1 List of Tables

    • 1.2 List of Figures

  • 2 Introduction

    • 2.1 What Is This Report About?

    • 2.2 Embolization Particle Procedures, Segmentation

    • 2.3 Definitions of Procedures Covered in the Report

  • 3 Embolization Particle Procedures, EU5

    • 3.1 Embolization Particle Procedures, EU5, 2015-2030

    • 3.2 Embolization Particle Procedures, EU5, 2015-2022

  • 4 Embolization Particle Procedures, France

    • 4.1 Embolization Particle Procedures, France, 2015-2030

      • 4.1.1 Embolization Particle Procedures to treat Arteriovenous Malformations, France, 2015-2030

      • 4.1.2 Embolization Particle Procedures to treat Benign prostatic hyperplasia, France, 2015-2030

      • 4.1.3 Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, France, 2015-2030

      • 4.1.4 Embolization Particle Procedures to treat Hepatocellular Carcinoma, France, 2015-2030

      • 4.1.5 Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, France, 2015-2030

      • 4.1.6 Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, France, 2015-2030

      • 4.1.7 Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, France, 2015-2030

      • 4.1.8 Embolization Particle Procedures to treat Renal Cell Carcinoma, France, 2015-2030

      • 4.1.9 Embolization Particle Procedures to treat Uterine Fibroids, France, 2015-2030

  • 5 Embolization Particle Procedures, Germany

    • 5.1 Embolization Particle Procedures, Germany, 2015-2030

      • 5.1.1 Embolization Particle Procedures to treat Arteriovenous Malformations, Germany, 2015-2030

      • 5.1.2 Embolization Particle Procedures to treat Benign prostatic hyperplasia, Germany, 2015-2030

      • 5.1.3 Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Germany, 2015-2030

      • 5.1.4 Embolization Particle Procedures to treat Hepatocellular Carcinoma, Germany, 2015-2030

      • 5.1.5 Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Germany, 2015-2030

      • 5.1.6 Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, Germany, 2015-2030

      • 5.1.7 Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Germany, 2015-2030

      • 5.1.8 Embolization Particle Procedures to treat Renal Cell Carcinoma, Germany, 2015-2030

      • 5.1.9 Embolization Particle Procedures to treat Uterine Fibroids, Germany, 2015-2030

  • 6 Embolization Particle Procedures, Italy

    • 6.1 Embolization Particle Procedures, Italy, 2015-2030

      • 6.1.1 Embolization Particle Procedures to treat Arteriovenous Malformations, Italy, 2015-2030

      • 6.1.2 Embolization Particle Procedures to treat Benign prostatic hyperplasia, Italy, 2015-2030

      • 6.1.3 Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Italy, 2015-2030

      • 6.1.4 Embolization Particle Procedures to treat Hepatocellular Carcinoma, Italy, 2015-2030

      • 6.1.5 Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Italy, 2015-2030

      • 6.1.6 Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, Italy, 2015-2030

      • 6.1.7 Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Italy, 2015-2030

      • 6.1.8 Embolization Particle Procedures to treat Renal Cell Carcinoma, Italy, 2015-2030

      • 6.1.9 Embolization Particle Procedures to treat Uterine Fibroids, Italy, 2015-2030

  • 7 Embolization Particle Procedures, Spain

    • 7.1 Embolization Particle Procedures, Spain, 2015-2030

      • 7.1.1 Embolization Particle Procedures to treat Arteriovenous Malformations, Spain, 2015-2030

      • 7.1.2 Embolization Particle Procedures to treat Benign prostatic hyperplasia, Spain, 2015-2030

      • 7.1.3 Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Spain, 2015-2030

      • 7.1.4 Embolization Particle Procedures to treat Hepatocellular Carcinoma, Spain, 2015-2030

      • 7.1.5 Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Spain, 2015-2030

      • 7.1.6 Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, Spain, 2015-2030

      • 7.1.7 Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Spain, 2015-2030

      • 7.1.8 Embolization Particle Procedures to treat Renal Cell Carcinoma, Spain, 2015-2030

      • 7.1.9 Embolization Particle Procedures to treat Uterine Fibroids, Spain, 2015-2030

  • 8 Embolization Particle Procedures, United Kingdom

    • 8.1 Embolization Particle Procedures, United Kingdom, 2015-2030

      • 8.1.1 Embolization Particle Procedures to treat Arteriovenous Malformations, United Kingdom, 2015-2030

      • 8.1.2 Embolization Particle Procedures to treat Benign prostatic hyperplasia, United Kingdom, 2015-2030

      • 8.1.3 Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, United Kingdom, 2015-2030

      • 8.1.4 Embolization Particle Procedures to treat Hepatocellular Carcinoma, United Kingdom, 2015-2030

      • 8.1.5 Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, United Kingdom, 2015-2030

      • 8.1.6 Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, United Kingdom, 2015-2030

      • 8.1.7 Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, United Kingdom, 2015-2030

      • 8.1.8 Embolization Particle Procedures to treat Renal Cell Carcinoma, United Kingdom, 2015-2030

      • 8.1.9 Embolization Particle Procedures to treat Uterine Fibroids, United Kingdom, 2015-2030

  • 9 Appendix

    • 9.1 Research Methodology

      • 9.1.1 Coverage

      • 9.1.2 Secondary Research

      • 9.1.3 Primary Research

      • 9.1.4 Market Modeling and Forecasting

      • 9.1.5 Company Share Analysis

      • 9.1.6 Distribution Share Analysis

      • 9.1.7 Benchmarking

    • 9.2 GlobalData Consulting

    • 9.3 Contact Us

    • 9.4 Disclaimer

Table

List of Tables_x000D_

Table 1: Embolization Particle Procedures, EU5, 2015-2030 15_x000D_

Table 2: Embolization Particle Procedures, EU5, 2015-2022 17_x000D_

Table 3: Embolization Particle Procedures, EU5, 2023-2030 19_x000D_

Table 4: Embolization Particle Procedures, France, 2015-2022 21_x000D_

Table 5: Embolization Particle Procedures, France, 2023-2030 23_x000D_

Table 6: Embolization Particle Procedures to treat Arteriovenous Malformations, France, 2015-2022 25_x000D_

Table 7: Embolization Particle Procedures to treat Arteriovenous Malformations, France, 2023-2030 27_x000D_

Table 8: Embolization Particle Procedures to treat Benign prostatic hyperplasia, France, 2015-2022 29_x000D_

Table 9: Embolization Particle Procedures to treat Benign prostatic hyperplasia, France, 2023-2030 31_x000D_

Table 10: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, France, 2015-2022 33_x000D_

Table 11: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, France, 2023-2030 35_x000D_

Table 12: Embolization Particle Procedures to treat Hepatocellular Carcinoma, France, 2015-2022 37_x000D_

Table 13: Embolization Particle Procedures to treat Hepatocellular Carcinoma, France, 2023-2030 39_x000D_

Table 14: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, France, 2015-2022 41_x000D_

Table 15: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, France, 2023-2030 43_x000D_

Table 16: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, France, 2015-2022 45_x000D_

Table 17: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, France, 2023-2030 47_x000D_

Table 18: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, France, 2015-2022 49_x000D_

Table 19: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, France, 2023-2030 51_x000D_

Table 20: Embolization Particle Procedures to treat Renal Cell Carcinoma, France, 2015-2022 53_x000D_

Table 21: Embolization Particle Procedures to treat Renal Cell Carcinoma, France, 2023-2030 55_x000D_

Table 22: Embolization Particle Procedures to treat Uterine Fibroids, France, 2015-2022 57_x000D_

Table 23: Embolization Particle Procedures to treat Uterine Fibroids, France, 2023-2030 59_x000D_

Table 24: Embolization Particle Procedures, Germany, 2015-2022 61_x000D_

Table 25: Embolization Particle Procedures, Germany, 2023-2030 63_x000D_

Table 26: Embolization Particle Procedures to treat Arteriovenous Malformations, Germany, 2015-2022 65_x000D_

Table 27: Embolization Particle Procedures to treat Arteriovenous Malformations, Germany, 2023-2030 67_x000D_

Table 28: Embolization Particle Procedures to treat Benign prostatic hyperplasia, Germany, 2015-2022 69_x000D_

Table 29: Embolization Particle Procedures to treat Benign prostatic hyperplasia, Germany, 2023-2030 71_x000D_

Table 30: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Germany, 2015-2022 73_x000D_

Table 31: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Germany, 2023-2030 75_x000D_

Table 32: Embolization Particle Procedures to treat Hepatocellular Carcinoma, Germany, 2015-2022 77_x000D_

Table 33: Embolization Particle Procedures to treat Hepatocellular Carcinoma, Germany, 2023-2030 79_x000D_

Table 34: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Germany, 2015-2022 81_x000D_

Table 35: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Germany, 2023-2030 83_x000D_

Table 36: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, Germany, 2015-2022 85_x000D_

Table 37: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, Germany, 2023-2030 87_x000D_

Table 38: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Germany, 2015-2022 89_x000D_

Table 39: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Germany, 2023-2030 91_x000D_

Table 40: Embolization Particle Procedures to treat Renal Cell Carcinoma, Germany, 2015-2022 93_x000D_

Table 41: Embolization Particle Procedures to treat Renal Cell Carcinoma, Germany, 2023-2030 95_x000D_

Table 42: Embolization Particle Procedures to treat Uterine Fibroids, Germany, 2015-2022 97_x000D_

Table 43: Embolization Particle Procedures to treat Uterine Fibroids, Germany, 2023-2030 99_x000D_

Table 44: Embolization Particle Procedures, Italy, 2015-2022 101_x000D_

Table 45: Embolization Particle Procedures, Italy, 2023-2030 103_x000D_

Table 46: Embolization Particle Procedures to treat Arteriovenous Malformations, Italy, 2015-2022 105_x000D_

Table 47: Embolization Particle Procedures to treat Arteriovenous Malformations, Italy, 2023-2030 107_x000D_

Table 48: Embolization Particle Procedures to treat Benign prostatic hyperplasia, Italy, 2015-2022 109_x000D_

Table 49: Embolization Particle Procedures to treat Benign prostatic hyperplasia, Italy, 2023-2030 111_x000D_

Table 50: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Italy, 2015-2022 113_x000D_

Table 51: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Italy, 2023-2030 115_x000D_

Table 52: Embolization Particle Procedures to treat Hepatocellular Carcinoma, Italy, 2015-2022 117_x000D_

Table 53: Embolization Particle Procedures to treat Hepatocellular Carcinoma, Italy, 2023-2030 119_x000D_

Table 54: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Italy, 2015-2022 121_x000D_

Table 55: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Italy, 2023-2030 123_x000D_

Table 56: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, Italy, 2015-2022 125_x000D_

Table 57: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, Italy, 2023-2030 127_x000D_

Table 58: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Italy, 2015-2022 129_x000D_

Table 59: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Italy, 2023-2030 131_x000D_

Table 60: Embolization Particle Procedures to treat Renal Cell Carcinoma, Italy, 2015-2022 133_x000D_

Table 61: Embolization Particle Procedures to treat Renal Cell Carcinoma, Italy, 2023-2030 135_x000D_

Table 62: Embolization Particle Procedures to treat Uterine Fibroids, Italy, 2015-2022 137_x000D_

Table 63: Embolization Particle Procedures to treat Uterine Fibroids, Italy, 2023-2030 139_x000D_

Table 64: Embolization Particle Procedures, Spain, 2015-2022 141_x000D_

Table 65: Embolization Particle Procedures, Spain, 2023-2030 143_x000D_

Table 66: Embolization Particle Procedures to treat Arteriovenous Malformations, Spain, 2015-2022 145_x000D_

Table 67: Embolization Particle Procedures to treat Arteriovenous Malformations, Spain, 2023-2030 147_x000D_

Table 68: Embolization Particle Procedures to treat Benign prostatic hyperplasia, Spain, 2015-2022 149_x000D_

Table 69: Embolization Particle Procedures to treat Benign prostatic hyperplasia, Spain, 2023-2030 151_x000D_

Table 70: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Spain, 2015-2022 153_x000D_

Table 71: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Spain, 2023-2030 155_x000D_

Table 72: Embolization Particle Procedures to treat Hepatocellular Carcinoma, Spain, 2015-2022 157_x000D_

Table 73: Embolization Particle Procedures to treat Hepatocellular Carcinoma, Spain, 2023-2030 159_x000D_

Table 74: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Spain, 2015-2022 161_x000D_

Table 75: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Spain, 2023-2030 163_x000D_

Table 76: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, Spain, 2015-2022 165_x000D_

Table 77: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, Spain, 2023-2030 167_x000D_

Table 78: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Spain, 2015-2022 169_x000D_

Table 79: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Spain, 2023-2030 171_x000D_

Table 80: Embolization Particle Procedures to treat Renal Cell Carcinoma, Spain, 2015-2022 173_x000D_

Table 81: Embolization Particle Procedures to treat Renal Cell Carcinoma, Spain, 2023-2030 175_x000D_

Table 82: Embolization Particle Procedures to treat Uterine Fibroids, Spain, 2015-2022 177_x000D_

Table 83: Embolization Particle Procedures to treat Uterine Fibroids, Spain, 2023-2030 179_x000D_

Table 84: Embolization Particle Procedures, United Kingdom, 2015-2022 181_x000D_

Table 85: Embolization Particle Procedures, United Kingdom, 2023-2030 183_x000D_

Table 86: Embolization Particle Procedures to treat Arteriovenous Malformations, United Kingdom, 2015-2022 185_x000D_

Table 87: Embolization Particle Procedures to treat Arteriovenous Malformations, United Kingdom, 2023-2030 187_x000D_

Table 88: Embolization Particle Procedures to treat Benign prostatic hyperplasia, United Kingdom, 2015-2022 189_x000D_

Table 89: Embolization Particle Procedures to treat Benign prostatic hyperplasia, United Kingdom, 2023-2030 191_x000D_

Table 90: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, United Kingdom, 2015-2022 193_x000D_

Table 91: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, United Kingdom, 2023-2030 195_x000D_

Table 92: Embolization Particle Procedures to treat Hepatocellular Carcinoma, United Kingdom, 2015-2022 197_x000D_

Table 93: Embolization Particle Procedures to treat Hepatocellular Carcinoma, United Kingdom, 2023-2030 199_x000D_

Table 94: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, United Kingdom, 2015-2022 201_x000D_

Table 95: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, United Kingdom, 2023-2030 203_x000D_

Table 96: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, United Kingdom, 2015-2022 205_x000D_

Table 97: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, United Kingdom, 2023-2030 207_x000D_

Table 98: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, United Kingdom, 2015-2022 209_x000D_

Table 99: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, United Kingdom, 2023-2030 211_x000D_

Table 100: Embolization Particle Procedures to treat Renal Cell Carcinoma, United Kingdom, 2015-2022 213_x000D_

Table 101: Embolization Particle Procedures to treat Renal Cell Carcinoma, United Kingdom, 2023-2030 215_x000D_

Table 102: Embolization Particle Procedures to treat Uterine Fibroids, United Kingdom, 2015-2022 217_x000D_

Table 103: Embolization Particle Procedures to treat Uterine Fibroids, United Kingdom, 2023-2030 219_x000D_

Table 104: Total Number of Primary Research Participants, General Surgery Market, by Country 222

Figures

List of Figures_x000D_

Figure 1: Embolization Particle Procedures, EU5, 2015-2030 14_x000D_

Figure 2: Embolization Particle Procedures, EU5, 2015-2022 16_x000D_

Figure 3: Embolization Particle Procedures, EU5, 2023-2030 18_x000D_

Figure 4: Embolization Particle Procedures, France, 2015-2022 20_x000D_

Figure 5: Embolization Particle Procedures, France, 2023-2030 22_x000D_

Figure 6: Embolization Particle Procedures to treat Arteriovenous Malformations, France, 2015-2022 24_x000D_

Figure 7: Embolization Particle Procedures to treat Arteriovenous Malformations, France, 2023-2030 26_x000D_

Figure 8: Embolization Particle Procedures to treat Benign prostatic hyperplasia, France, 2015-2022 28_x000D_

Figure 9: Embolization Particle Procedures to treat Benign prostatic hyperplasia, France, 2023-2030 30_x000D_

Figure 10: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, France, 2015-2022 32_x000D_

Figure 11: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, France, 2023-2030 34_x000D_

Figure 12: Embolization Particle Procedures to treat Hepatocellular Carcinoma, France, 2015-2022 36_x000D_

Figure 13: Embolization Particle Procedures to treat Hepatocellular Carcinoma, France, 2023-2030 38_x000D_

Figure 14: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, France, 2015-2022 40_x000D_

Figure 15: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, France, 2023-2030 42_x000D_

Figure 16: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, France, 2015-2022 44_x000D_

Figure 17: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, France, 2023-2030 46_x000D_

Figure 18: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, France, 2015-2022 48_x000D_

Figure 19: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, France, 2023-2030 50_x000D_

Figure 20: Embolization Particle Procedures to treat Renal Cell Carcinoma, France, 2015-2022 52_x000D_

Figure 21: Embolization Particle Procedures to treat Renal Cell Carcinoma, France, 2023-2030 54_x000D_

Figure 22: Embolization Particle Procedures to treat Uterine Fibroids, France, 2015-2022 56_x000D_

Figure 23: Embolization Particle Procedures to treat Uterine Fibroids, France, 2023-2030 58_x000D_

Figure 24: Embolization Particle Procedures, Germany, 2015-2022 60_x000D_

Figure 25: Embolization Particle Procedures, Germany, 2023-2030 62_x000D_

Figure 26: Embolization Particle Procedures to treat Arteriovenous Malformations, Germany, 2015-2022 64_x000D_

Figure 27: Embolization Particle Procedures to treat Arteriovenous Malformations, Germany, 2023-2030 66_x000D_

Figure 28: Embolization Particle Procedures to treat Benign prostatic hyperplasia, Germany, 2015-2022 68_x000D_

Figure 29: Embolization Particle Procedures to treat Benign prostatic hyperplasia, Germany, 2023-2030 70_x000D_

Figure 30: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Germany, 2015-2022 72_x000D_

Figure 31: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Germany, 2023-2030 74_x000D_

Figure 32: Embolization Particle Procedures to treat Hepatocellular Carcinoma, Germany, 2015-2022 76_x000D_

Figure 33: Embolization Particle Procedures to treat Hepatocellular Carcinoma, Germany, 2023-2030 78_x000D_

Figure 34: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Germany, 2015-2022 80_x000D_

Figure 35: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Germany, 2023-2030 82_x000D_

Figure 36: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, Germany, 2015-2022 84_x000D_

Figure 37: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, Germany, 2023-2030 86_x000D_

Figure 38: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Germany, 2015-2022 88_x000D_

Figure 39: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Germany, 2023-2030 90_x000D_

Figure 40: Embolization Particle Procedures to treat Renal Cell Carcinoma, Germany, 2015-2022 92_x000D_

Figure 41: Embolization Particle Procedures to treat Renal Cell Carcinoma, Germany, 2023-2030 94_x000D_

Figure 42: Embolization Particle Procedures to treat Uterine Fibroids, Germany, 2015-2022 96_x000D_

Figure 43: Embolization Particle Procedures to treat Uterine Fibroids, Germany, 2023-2030 98_x000D_

Figure 44: Embolization Particle Procedures, Italy, 2015-2022 100_x000D_

Figure 45: Embolization Particle Procedures, Italy, 2023-2030 102_x000D_

Figure 46: Embolization Particle Procedures to treat Arteriovenous Malformations, Italy, 2015-2022 104_x000D_

Figure 47: Embolization Particle Procedures to treat Arteriovenous Malformations, Italy, 2023-2030 106_x000D_

Figure 48: Embolization Particle Procedures to treat Benign prostatic hyperplasia, Italy, 2015-2022 108_x000D_

Figure 49: Embolization Particle Procedures to treat Benign prostatic hyperplasia, Italy, 2023-2030 110_x000D_

Figure 50: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Italy, 2015-2022 112_x000D_

Figure 51: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Italy, 2023-2030 114_x000D_

Figure 52: Embolization Particle Procedures to treat Hepatocellular Carcinoma, Italy, 2015-2022 116_x000D_

Figure 53: Embolization Particle Procedures to treat Hepatocellular Carcinoma, Italy, 2023-2030 118_x000D_

Figure 54: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Italy, 2015-2022 120_x000D_

Figure 55: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Italy, 2023-2030 122_x000D_

Figure 56: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, Italy, 2015-2022 124_x000D_

Figure 57: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, Italy, 2023-2030 126_x000D_

Figure 58: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Italy, 2015-2022 128_x000D_

Figure 59: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Italy, 2023-2030 130_x000D_

Figure 60: Embolization Particle Procedures to treat Renal Cell Carcinoma, Italy, 2015-2022 132_x000D_

Figure 61: Embolization Particle Procedures to treat Renal Cell Carcinoma, Italy, 2023-2030 134_x000D_

Figure 62: Embolization Particle Procedures to treat Uterine Fibroids, Italy, 2015-2022 136_x000D_

Figure 63: Embolization Particle Procedures to treat Uterine Fibroids, Italy, 2023-2030 138_x000D_

Figure 64: Embolization Particle Procedures, Spain, 2015-2022 140_x000D_

Figure 65: Embolization Particle Procedures, Spain, 2023-2030 142_x000D_

Figure 66: Embolization Particle Procedures to treat Arteriovenous Malformations, Spain, 2015-2022 144_x000D_

Figure 67: Embolization Particle Procedures to treat Arteriovenous Malformations, Spain, 2023-2030 146_x000D_

Figure 68: Embolization Particle Procedures to treat Benign prostatic hyperplasia, Spain, 2015-2022 148_x000D_

Figure 69: Embolization Particle Procedures to treat Benign prostatic hyperplasia, Spain, 2023-2030 150_x000D_

Figure 70: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Spain, 2015-2022 152_x000D_

Figure 71: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, Spain, 2023-2030 154_x000D_

Figure 72: Embolization Particle Procedures to treat Hepatocellular Carcinoma, Spain, 2015-2022 156_x000D_

Figure 73: Embolization Particle Procedures to treat Hepatocellular Carcinoma, Spain, 2023-2030 158_x000D_

Figure 74: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Spain, 2015-2022 160_x000D_

Figure 75: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, Spain, 2023-2030 162_x000D_

Figure 76: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, Spain, 2015-2022 164_x000D_

Figure 77: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, Spain, 2023-2030 166_x000D_

Figure 78: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Spain, 2015-2022 168_x000D_

Figure 79: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, Spain, 2023-2030 170_x000D_

Figure 80: Embolization Particle Procedures to treat Renal Cell Carcinoma, Spain, 2015-2022 172_x000D_

Figure 81: Embolization Particle Procedures to treat Renal Cell Carcinoma, Spain, 2023-2030 174_x000D_

Figure 82: Embolization Particle Procedures to treat Uterine Fibroids, Spain, 2015-2022 176_x000D_

Figure 83: Embolization Particle Procedures to treat Uterine Fibroids, Spain, 2023-2030 178_x000D_

Figure 84: Embolization Particle Procedures, United Kingdom, 2015-2022 180_x000D_

Figure 85: Embolization Particle Procedures, United Kingdom, 2023-2030 182_x000D_

Figure 86: Embolization Particle Procedures to treat Arteriovenous Malformations, United Kingdom, 2015-2022 184_x000D_

Figure 87: Embolization Particle Procedures to treat Arteriovenous Malformations, United Kingdom, 2023-2030 186_x000D_

Figure 88: Embolization Particle Procedures to treat Benign prostatic hyperplasia, United Kingdom, 2015-2022 188_x000D_

Figure 89: Embolization Particle Procedures to treat Benign prostatic hyperplasia, United Kingdom, 2023-2030 190_x000D_

Figure 90: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, United Kingdom, 2015-2022 192_x000D_

Figure 91: Embolization Particle Procedures to treat Colorectal Cancer with Metastatic Liver Disease, United Kingdom, 2023-2030 194_x000D_

Figure 92: Embolization Particle Procedures to treat Hepatocellular Carcinoma, United Kingdom, 2015-2022 196_x000D_

Figure 93: Embolization Particle Procedures to treat Hepatocellular Carcinoma, United Kingdom, 2023-2030 198_x000D_

Figure 94: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, United Kingdom, 2015-2022 200_x000D_

Figure 95: Embolization Particle Procedures to treat Intrahepatic cholangiocarcinoma, United Kingdom, 2023-2030 202_x000D_

Figure 96: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, United Kingdom, 2015-2022 204_x000D_

Figure 97: Embolization Particle Procedures to treat Neuroendocrine tumors with Metastatic Liver Disease, United Kingdom, 2023-2030 206_x000D_

Figure 98: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, United Kingdom, 2015-2022 208_x000D_

Figure 99: Embolization Particle Procedures to treat Other tumors with Metastatic Liver Disease, United Kingdom, 2023-2030 210_x000D_

Figure 100: Embolization Particle Procedures to treat Renal Cell Carcinoma, United Kingdom, 2015-2022 212_x000D_

Figure 101: Embolization Particle Procedures to treat Renal Cell Carcinoma, United Kingdom, 2023-2030 214_x000D_

Figure 102: Embolization Particle Procedures to treat Uterine Fibroids, United Kingdom, 2015-2022 216_x000D_

Figure 103: Embolization Particle Procedures to treat Uterine Fibroids, United Kingdom, 2023-2030 218

Frequently asked questions

EU5 Embolization Particle Procedures Count by Segments and Forecast to 2030 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

Most Popular
$7,990

Can be shared by unlimited users within one corporate location e.g. a regional office

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Add to Basket

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

EU5 Embolization Particle Procedures Count by Segments and Forecast to 2030 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

 Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

 Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

 Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

 Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

 Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

 Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

 Senior Account Manager, TSYS

Related reports

View more Embolization Particles reports
Medical Devices
Germany Surgical Stapling Devices Market Size (Value, Volume, ASP) by…
$500 | November 2020
Medical Devices
India Surgical Energy Instruments Market Size (Value, Volume, ASP) by…
$500 | November 2020
Medical Devices
Japan Surgical Energy Instruments Market Size (Value, Volume, ASP) by…
$500 | November 2020
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at EU5 Embolization Particle Procedures Count by Segments and Forecast to 2030 in real time.

  • Access a live EU5 Embolization Particle Procedures Count by Segments and Forecast to 2030 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.
Tell me more